Education
About Us
Working with TipRanks
Follow Us
Newamsterdam Pharma Company N.V. (NAMS)
:NAMS
RESEARCH TOOLSreports
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 45.56M | $ 12.76M | $ 95.91M | $ 0.00 | $ 0.00 |
| Gross Profit | $ 45.56M | $ 12.76M | $ 95.91M | $ 0.00 | $ 0.00 |
| Operating Income | $ -176.29M | $ -165.73M | $ -3.32M | $ -30.73M | $ -5.43M |
| EBITDA | $ -241.49M | $ -176.86M | $ -3.31M | $ -30.73M | $ -5.43M |
| Net Income | $ -241.60M | $ -176.94M | $ -21.14M | $ -36.71M | $ -5.75M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 834.19M | $ 340.45M | $ 438.52M | $ 53.09M | $ 7.86M |
| Total Assets | $ 864.62M | $ 347.10M | $ 531.58M | $ 59.78M | $ 9.23M |
| Total Debt | $ 448.00K | $ 60.00K | $ 118.00K | $ 164.00K | $ 11.65M |
| Net Debt | $ -771.29M | $ -340.39M | $ -438.40M | $ -52.93M | $ 3.79M |
| Total Liabilities | $ 107.12M | $ 58.70M | $ 47.06M | $ 9.99M | $ 12.81M |
| Stockholders' Equity | $ 757.50M | $ 288.39M | $ 484.52M | $ 49.79M | $ -3.58M |
| Cash Flow | |||||
| Free Cash Flow | $ -159.24M | $ -141.24M | $ 7.96M | $ -25.18M | $ -5.98M |
| Operating Cash Flow | $ -158.56M | $ -141.22M | $ 7.97M | $ -25.16M | $ -5.97M |
| Investing Cash Flow | $ -62.85M | $ -24.00K | $ 715.00K | $ -20.00K | $ -13.00K |
| Financing Cash Flow | $ 659.51M | $ 8.91M | $ 375.18M | $ 68.99M | $ 11.32M |
NewAmsterdam Pharma Company Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.